Reports
Sale
Global Plasma Derived Therapy Market Size, Share, Trends, Forecast: By Product: Immunoglobulin, Coagulation factors, Albumin, Others; By Applications: Hemophilia, Primary immunodeficiency disease, Idiopathic thrombocytopenic purpura, Others; Regional Analysis; Regulatory Framework; Patent Analysis; Supplier Landscape; 2024-2032
Global Plasma Derived Therapy Market Outlook
The global plasma derived therapy market size was valued at USD 24.00 billion in 2023, driven by the increasing access to medical care across the globe. The market size is anticipated to grow at a CAGR of 6.9% during the forecast period of 2024-2032 to achieve a value of USD 43.75 billion by 2032.
Plasma Derived Therapy: Introduction
Plasma-derived medicinal products are majorly used in immunology, haemostasis, and intensive care to treat rare, serious, genetic and – in many cases – life threatening diseases or conditions. These include over 80 recognized primary immunodeficiency diseases, bleeding disorders such as haemophilia and von Willebrand disease, and other genetic disorders relating to missing or non-functioning proteins typically found in blood plasma. Although they affect a relatively small percentage of the population, most are chronic conditions.
Patients generally require regular infusions or injections throughout their lives, ranging from twice a week to once a month for a primary immunodeficiency. These therapies are a lifeline, allowing patients to live a relatively normal life or significantly extending life expectancy. Plasma is a key component in the production of PDMPs. PDMPs are derived from human plasma, which is collected from donors and processed into various products. Plasma is a strategic resource to produce PDMPs, and its availability is crucial for the treatment of patients with rare diseases.
Global Plasma Derived Therapy Market Analysis
The rising investment and funding by the governments in advanced technology, along with the rising capacity expansion by the key players is primarily driving the plasma derived therapy market growth.
Plasma derived medicinal products (PDMPs) play a crucial role in prophylaxis and treatment of patients suffering from immune deficiencies, autoimmune and inflammatory diseases, bleeding disorders, and a variety of congenital deficiency disorders as well. They are used for treatment or prevention of rare clinical conditions that affects around 5 out of 10,000 people. PDMPs can be divided into four categories which are replacement or substitution therapies, immune-modulating therapies, anti-inflammatory therapies, and therapies directed to plasma protein antagonist functions. The increasing demand for PDMPs is growing gradually which is driven by increased access to medical care globally, new product launches and indications, introduction of more patient-friendly applications, and diagnostic advances that are further fuelling the global plasma derived therapy market expansion.
The development and availability of PDMPs is also expected to face some challenges due to the small size of the patient population as it would keep the costs high for the development of medicines for rare diseases.
Global Plasma Derived Therapy Market Segmentations
Market Breakup by Product
- Immunoglobulin
- Coagulation Factors
- Albumin
- Others
Market Breakup by Applications
- Hemophilia
- Primary immunodeficiency disease
- Idiopathic thrombocytopenic purpura
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Plasma Derived Therapy Market Overview
The rising geriatric population is contributing to the growth of the market. Factors such as increasing prevalence of genetic disorders, escalating use of plasma proteins in pharmaceuticals, surging autoimmune disorders, government initiatives, rising demand for albumin are also directly driving the global plasma derived therapy market development.
Factors such as increased use of immunoglobulin is also fueling the market growth. With evident improvement in diagnoses of rare diseases and earlier treatment of complex chronic diseases, the demand for PDTs has increased significantly over the last two decades. The demand for plasma derived medicinal products and therapies is increasing with, new products and indications, increased access to medical care, more patient-friendly applications, and diagnostic advances has also been adding further value to the plasma derived therapy market share. According to several international data resources it is observed that a large number of patients around the globe are not yet diagnosed with diseases that require PDMP treatment.
There are chances of these therapies becoming expensive to access in future but with rise in development of new products and expanding markets it is expected to avoid the chances of that happening which will further contribute to the demand of the plasma derived therapies in the market. There has also been an evident increase in collaborations between key players two develop new products and therapies to serve more patients which is also responsible for driving the market growth.
Plasma Derived Therapy Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- CSL Behring
- Takeda Pharmaceutical Company Limited
- BPL
- ADMA Biologics
- Biotest AG
- Octapharma
- Grifols
- Kamada Pharmaceuticals
- SK Plasma
- Kedrion
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Applications |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Plasma Derived Therapy Market Overview
3.1 Plasma Derived Therapy Market Historical Value (2017-2023)
3.2 Plasma Derived Therapy Market Forecast Value (2024-2032)
4 Plasma Derived Therapy Market Landscape
4.1 Lentiviral Vectors: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Lentiviral Vectors: Product Landscape
4.2.1 Analysis by Products
4.2.2 Analysis by Applications
5 Plasma Derived Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Plasma Derived Therapy Market Segmentation
6.1 Plasma Derived Therapy Market by Product
6.1.1 Market Overview
6.1.2 Immunoglobulin
6.1.3 Coagulation factors
6.1.4 Albumin
6.1.5 Others
6.2 Plasma Derived Therapy Market by Applications
6.2.1 Market Overview
6.2.2 Hemophilia
6.2.3 Primary immunodeficiency disease
6.2.4 Idiopathic thrombocytopenic purpura
6.2.5 Others
6.3 Plasma Derived Therapy Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Plasma Derived Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Plasma Derived Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Plasma Derived Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Plasma Derived Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Plasma Derived Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 CSL Behring
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Takeda Pharmaceutical Company Limited
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 BPL
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 ADMA Biologics
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Biotest AG
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Octapharma
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Grifols
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Kamada Pharmaceuticals
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 SK Plasma
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Kedrion
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
Plasma derived therapy refers to treatments which are derived from human plasma. Human plasma is the clear, liquid portion of blood that remains after blood cells, platelets, and other cellular components are eliminated. It consists of water, salts, enzymes, and antibodies, among other proteins.
The market attained a value of about USD 24.00 billion in 2023, driven by the increasing geriatric population.
The market is anticipated to grow at a CAGR of 6.9% during the forecast period of 2024-2032, likely to reach a market value of USD 43.75 billion by 2032.
The increasing prevalence of rare diseases and development of new products are among the major factors driving the market growth.
Rising investments and collaborations between the key players to develop new innovative therapies to cater more patients are strongly influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Types of products in the market include immunoglobulin, coagulation factors, albumin, among others.
They find wide applications in hemophilia, primary immunodeficiency disease, and idiopathic thrombocytopenic purpura, among others.
Key players involved in the market are CSL Behring, Takeda Pharmaceutical Company Limited, BPL, ADMA Biologics, Biotest AG, Octapharma, Grifols, Kamada Pharmaceuticals, SK Plasma, and Kedrion.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER